Skip to main content

From the Helm: Clarity Pharmaceuticals Executive Chairman, Alan Taylor

Bell Direct
May 24, 2024

Embark on a journey of discovery with Dr. Alan as he unveils the cutting-edge breakthroughs of Clarity Pharma, a pioneering force in the relentless fight against cancer through next-generation radiopharmaceuticals. In this instalment of our From the helm series, Bell Direct’s Grady Wulff speaks to Clarity Pharmaceuticals (ASX:CU6) Executive Chairman, Dr Alan Taylor.

Clarity Pharmaceuticals specialises in the development of Targeted Copper Theragnostic for the imaging and treatment of selected cancers. Clarity Pharma has an extensive program of clinical development for imaging and cancer therapy with a series of important data readouts over the next few years.

In this video Dr. Alan discusses:

  • (1:27) an overview of the company, including their 7 clinical trials
  • (3:35) the promising results from their SECuRE trial
  • (11:55) why the radiopharmaceutical market is booming
  • (14:47) why Clarity Pharma could be an investment opportunity.

Morning Bell 31 March

Bell Direct
March 31, 2025

Weekly Wrap 28 March

Bell Direct
March 28, 2025

Morning Bell 27 March

Bell Direct
March 27, 2025

Morning Bell 26 March

Sam Kanaan
March 26, 2025

Morning Bell 25 March

Grady Wulff
March 25, 2025

Morning Bell 24 March

Grady Wulff
March 24, 2025

Weekly Wrap 21 March

Bell Direct
March 21, 2025

Morning Bell 20 March

Bell Direct
March 20, 2025

Morning Bell 19 March

Bell Direct
March 19, 2025

Morning Bell 18 March

Bell Direct
March 18, 2025

Morning Bell 17 March

Bell Direct
March 17, 2025